使用ADNI量化阿尔茨海默病连续性中的自然粉样蛋白斑块积累
Marwa E Elhefnawy1,2, Noel Patson1,3, Samer Mouksassi1,4
1Applied Pharmacometrics Training-Africa Program, c/o Pharmacometrics Africa NPC, Cape Town, South Africa.
Journal of pharmacokinetics and pharmacodynamics
|January 25, 2025
概括
大脑粉样质斑块的积累,阿尔茨海默病 (AD) 的风险因素,呈指数级增长. 这项研究模拟了粉样斑块的进展,确定了诸如年龄和APOE4基因型等关键影响因素.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
- 阿尔茨海默氏症疾病的发病因子
背景情况:
- 大脑粉样β神经质斑块的积累与阿尔茨海默病 (AD) 风险的增加有关.
- 之前的研究估计了粉样斑块变化,但缺乏非线性混合效应建模.
- 需要模型来捕捉整个AD频谱的粉样斑块进展动态.
研究的目的:
- 用非线性混合效应模型描述粉样蛋白积累的自然进展.
- 量化粉样斑块进展率的群体平均值和参与者之间的变异性.
- 为了确定影响基线和内在粉样蛋白斑块积累率的因素.
主要方法:
- 利用了超过10年的1,340名阿尔茨海默病神经成像计划 (ADNI) 参与者的数据.
- 雇佣的18F-florbetapir正子发射断层扫描 (PET) 扫描用于粉样质斑块检测.
- 应用非线性混合效应建模与逐步共变量建模 (SCM).
主要成果:
- 粉样蛋白斑块水平在10年内遵循指数增长模式,其内在速率约为每年3个粉样蛋白单位.
- 基线粉样蛋白水平受到年龄,性别,APOE4基因型和疾病阶段的影响.
- 与非携带者相比,APOE4同胞载体的平均基线粉样蛋白水平较高.
结论:
- 这项研究为阿尔茨海默氏病连续性中的自然粉样质斑块进展提供了一个全面的模型.
- 确定了影响粉样蛋白积累的显著的人口和遗传因素.
- 这些发现有助于理解AD的发病因子,并可能为未来的治疗策略提供信息.
相关概念视频
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160


